October 2015

Contents

Editorial

• Sept/Oct 2015: Volume 16 Number 9/10

Supplements

• Two new i-Base resources: Introduction to ART booklet and a Pocket ART leaflet

Conference reports

• 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-21 September 2015, San Diego

• No transmission of integrase-resistant HIV seen in California cohort

• Doubled hypogonadism rate in middle-aged men with HIV: fat is a factor

• Protection against flu but not HBV in vaccinated perinatally HIV-infected children

• 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), 19-22 July 2015, Vancouver, Canada

• The PrEP experience: IAS 2015 and beyond

• Raltegravir for neonates will require a complicated dosing regimen

• News and notes on HIV cure research from IAS 2015

• 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 26-28 May 2015, Washington DC

• Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel

• Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives

• Pharmacokinetics of four antiretrovirals in pregnancy: data from the PANNA network

• Dolutegravir placental transfer moderate in ex vivo model

• Paediatric dosing of DRV/r

Antiretrovirals

• FDA approve additional weight band dosing for children using atazanavir powder

Treatment access

• Why the 5000% price hike for pyrimethamine in the US is relevant in the UK

• Proposed TTIP trade agreement in Europe: Report shows European Commission’s access to medicines commitments are ‘empty gestures’

• Australian doctors advice for buying generic sofosbuvir for HepC

Guidelines

• UK BHIVA treatment guidelines for HIV positive adults (2015)

• WHO guidelines for when to start ART and use of PrEP (September 2015)

Side effects

• Neurocognitive disorder, persistent inverted CD4:CD8 ratios and immune activation in the CNS

Hepatitis coinfection

• Gilead to provide free hepatitis drugs to treat all people liviing with hepatitis C in Iceland

HIV prevention and transmission

• i-Base Q&A resources on PrEP: increased use of off-label PrEP in the UK shows need for NHS support and risk to PEP services

• Two new UK community PrEP websites

• First UK NHS PrEP support service launched at 56 Dean Street, Soho

• UK PROUD study published as open access article in The Lancet: PrEP dramatically reduces risk of HIV

Cure-related research

• Combining PKC agonists and bromodomain inhibitors to reverse HIV latency

• Estimating how frequently latent HIV reactivates

Other news

• Professor Clive Loveday awarded a Royal Order of Chivalry

On the web

• New music video on results from the START study: “Now we know”

• UK PROUD study published as open access article in the Lancet

PDFs

• September/October 2015: Volume 16 Number 9/10